Profit Margin (Annual)

Profit Margin: Net Income as a portion of total sales revenue. Calculated as: Net Income / Total Revenues

Astellas Pharma Inc. (ALPMY) had Profit Margin of 13.63% for the most recently reported fiscal year, ending 2026-03-31.

Quarterly Annual

Figures for fiscal year ending 2026-03-31

Income Statement Financials
Revenue	$13.45B
Net Income	$1.83B
Cost of Goods Sold	$2.57B
Gross Profit	$10.88B
Operating Expenses	$11.05B
Operating Income	$2.40B
Non-Operating Income/Expense	$-39.00M
Pre-Tax Income	$2.37B
Normalized Pre-Tax Income	$2.37B
Income after Taxes	$1.83B
Income from Continuous Operations	$1.83B
Consolidated Net Income/Loss	$1.83B
Normalized Income after Taxes	$1.83B
EBIT	$2.40B
EBITDA	$3.63B
Weighted-Average Shares Outstanding (Basic)	1.79B
Weighted-Average Shares Outstanding (Diluted)	1.80B
Earnings per Share (EPS) (Basic)	$1.02
Earnings per Share (EPS) (Diluted)	$1.02
Balance Sheet Financials
Current Assets	$8.94B
Property, Plant, and Equipment	$2.25B
Long-Term Assets	$13.49B
Total Assets	$22.43B
Current Liabilities	$7.66B
Long-Term Debt	$2.01B
Long-Term Liabilities	$3.26B
Total Liabilities	$10.92B
Common Equity	$11.52B
Tangible Shareholders Equity	$2.47B
Shareholders Equity	$11.52B
Common Shares Outstanding	1.79B
Cash Flow Statement Financials
Cash Flow from Operating Activities	$3.52B
Cash Flow from Investing Activities	$-420.00M
Cash Flow from Financial Activities	$-2.55B
Beginning Cash	$1.19B
End Cash	$1.77B
Increase/Decrease in Cash	$586.00M
Stock-Based Compensation	--
Common Stock Dividends Paid	$-856.00M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.17
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.15
Debt to Equity Ratio	0.32
Gross Margin	80.91%
Operating Margin	17.88%
EBIT Margin	17.88%
EBITDA Margin	26.97%
Pre-Tax Profit Margin	17.60%
Profit Margin	13.63%
Free Cash Flow	$3.16B
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.60
Inventory Turnover	1.23
Receiveable Turnover	2.81
Days Sales in Receivables	129.98
Return on Equity	15.92%
Return on Tangible Equity	74.21%
Return on Assets	8.17%
Return on Investments	13.55%
Book Value Per Share	$6.43
Free Cash Flow per Share	$1.76
Operating Cash Flow per Share	$1.96

Data from Zacks Investment Research, Inc.